Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for treating purine metabolic disorder disease

A technology of xanthine oxidase and derivatives, which is applied in the application field of drugs for treating purine metabolic disorders, flavonoids and their modified derivatives, can solve the problems of long treatment period, achieve rapid curative effect, abundant drug sources, inhibit Effect of Xanthine Oxidase Activity

Active Publication Date: 2014-02-26
广东世信药业有限公司
View PDF2 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

From the perspective of curative effect, the curative effect of traditional Chinese medicine is not as fast as that of western medicine, and the course of treatment is longer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for treating purine metabolic disorder disease
  • Drug for treating purine metabolic disorder disease
  • Drug for treating purine metabolic disorder disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1: The situation that each solvent part of Smilax smilax inhibits XOD activity

[0043] Detection principle: XOD catalyzes xanthine to generate UA, and UA reacts with NBT (nitro blue tetrazolium chloride) to generate purple formazan. When the activity of XOD is inhibited, the amount of UA generated decreases, and purple formazan The generation of cum is reduced accordingly, and the size of the inhibitory activity is detected by measuring the absorbance of the generated purple formazan at 560nm.

[0044] Sample preparation: take 100 g of Smilax smilax, coarsely crush it, pass through a 40-mesh sieve, and use 15 times the amount, 10 times the amount, and 5 times the amount of 50% ethanol to extract 3 times, combine the percolation fluid, and recover until it has no alcohol smell. Dilute to 250ml with distilled water, which is the Smilax tuckahoe sample solution. Measure 25ml of Smilax smilax sample and place it in a separatory funnel, extract with petroleum et...

Embodiment 2

[0051] Example 2: Extraction and Purification of Astilbin in Smilax Smilax

[0052] Take 100g of Smilax smilax medicinal material, coarsely crush it, pass through a 40-mesh sieve, extract 3 times by percolation with 15 times, 10 times and 5 times of 50% ethanol, combine the percolation liquid, concentrate (30°C, d=1.15-1.20 ), add 95% ethanol twice the volume of the concentrated solution, stir evenly to produce a flocculent precipitate, then put it in a refrigerator at 4°C for 12h, and then centrifuge at 4000r / min for 30min. The supernatant was taken, and the ethanol was removed by rotary evaporation. Then wash twice with an appropriate amount of petroleum ether, dry, add 500ml of 50% ethanol to dissolve, and use polyamide resin adsorption method to purify. Water, 10% ethanol, and 50% ethanol were used as eluents respectively, and the 50% ethanol eluent was collected, concentrated and evaporated to dryness to obtain a light yellow substance. Through NMR, SM, IR and UV spectr...

Embodiment 3

[0053] Example 3: Influence on the inhibition of serum UA and XOD activities in rats with hyperuricemia.

[0054] All the rats in the test were SD rats, half of them were male and half were male. A total of 80, weighing 200-240g. 80 rats were taken and randomly divided into 4 groups including blank group, model group, drug group and colchicine group, 20 rats in each group. Except the blank group, the other groups were established with adenine 100mg / kg orally for one week. On the 5th day, astilbin 40 mg / kg and colchicine 40 mg / kg were given by intragastric administration to the drug group and colchicine group, respectively, for 5 consecutive days. The blank group and the model group were given equal volumes of distilled water, and each group was given 0.25ml / 25g body weight. On the 10th day of the experiment, 1 hour after the administration, the animals in each group were removed from the eyeballs to get blood, and the activities of UA and XOD in the serum of the rats were m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a drug for treating purine metabolic disorder disease, provides a flavonoids compound represented by the formula (I) and a modified derivative thereof, and a use in inhibition of xanthine oxidase activity and promotion of uric acid excretion function, wherein R1, R2 and R3 independently represent -H or monosaccharide residues, and R4 represents -H or -OH. In particular, the drug is used for treating purine metabolic disorder disease, and can be used for treating hyperuricemia and related diseases and reducing a individual serum UA level; the drug is used for treating hyperuricemia; the drug is used for treating the related diseases, such as for treating gouty arthritis and arthrophlogosis caused by hyperuricemia, and for treating chronic interstitial nephritis, kidney stones and the like caused by hyperuricemia. The drug has the advantages of natural chemical structure, safety, low toxicity, rapid curative effect and fewer side effects. (I).

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to the application of flavonoids and modified derivatives thereof and medicines for treating purine metabolic disorders. Background technique [0002] From the epidemiological data of developed countries in Europe and the United States and my country, the incidence of hyperuricemia (HUA) is increasing year by year. With the improvement of people's living standards, the diet structure tends to change towards high fat and high protein. In my country, the incidence of hyperuricemia not only increases with the improvement of living standards, but also the incidence of hyperuricemia tends to be younger. [0003] Hyperuricemia refers to a condition in which the human body has increased production and / or decreased excretion of serum uric acid (UA) due to purine metabolism disorders. Under a normal purine diet, if the serum UA level is higher than 420mmol / L for men and higher than 360mm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K31/352A61P19/06A61P19/02A61P13/12A61P13/04
Inventor 罗观堤谢秋彬
Owner 广东世信药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com